Abstract
The cytochromes P450 superfamily of enzymes is a group of hemeproteins That catalyze the metabolism of an extensive series of compounds including drugs, chemical carcinogens, fatty acids, and steroids. They oxidize substrates ranging in size from ethylene to cyclosporin. Although significant efforts have been made to obtain structural information on the active sites of the microbial P450s, relatively little is currently known regarding the identities of the critical amino acid residues in the P450 active sites that are involved in substrate binding and catalysis. Since information on the crystal structures of the eukaryotic P450s has been relatively limited, investigators have used a variety of other techniques in attempts to elucide the structural features that play a role in the catalytic properties and substrate specificity at the enzyme active site. These include site-directed mutagenesis, natural mutations, homology modeling, mapping with aryl-iron complexes, affinity and photoaffinity labeling, and mechanism-based inactivators. A variety of different mechanism-based inactivators have proven to be useful in identifiying active site amino acid residues involved in substrate binding and catalysis. In this review we present a sampling of the types of studies that can be conducted using mechanism-based inactivators and highlight studies with several classes of compounds including acetylenes, isothiocyanates, xanthates, aminobenzotriazoles, phencyclidine, and furanocoumarins. Labeled peptides isolated from the inactivated proteins have been analyzed by N-terminal amino acid sequencing in conjunction with mass spectrometry to determine the sites of covalent modification. Mechanistic studies aimed at identifying the basis for the inactivation following adduct formation are also presented.
Keywords: Cytochrome P450, homology modeling, Mapping, aminobenzotriazoles, phencyclidine, furanocoumarins, Acetylenes, isothiocyanates, xanthates, 2-ethynylnaphthalene, 9-ethynylphenanthrene
Current Drug Metabolism
Title: Mechanism-Based Inactivators as Probes of Cytochrome P450 Structure and Function
Volume: 2 Issue: 3
Author(s): Ute M. Kent, Monica I. Jushchhyshyn and Paul F. Hollenberg
Affiliation:
Keywords: Cytochrome P450, homology modeling, Mapping, aminobenzotriazoles, phencyclidine, furanocoumarins, Acetylenes, isothiocyanates, xanthates, 2-ethynylnaphthalene, 9-ethynylphenanthrene
Abstract: The cytochromes P450 superfamily of enzymes is a group of hemeproteins That catalyze the metabolism of an extensive series of compounds including drugs, chemical carcinogens, fatty acids, and steroids. They oxidize substrates ranging in size from ethylene to cyclosporin. Although significant efforts have been made to obtain structural information on the active sites of the microbial P450s, relatively little is currently known regarding the identities of the critical amino acid residues in the P450 active sites that are involved in substrate binding and catalysis. Since information on the crystal structures of the eukaryotic P450s has been relatively limited, investigators have used a variety of other techniques in attempts to elucide the structural features that play a role in the catalytic properties and substrate specificity at the enzyme active site. These include site-directed mutagenesis, natural mutations, homology modeling, mapping with aryl-iron complexes, affinity and photoaffinity labeling, and mechanism-based inactivators. A variety of different mechanism-based inactivators have proven to be useful in identifiying active site amino acid residues involved in substrate binding and catalysis. In this review we present a sampling of the types of studies that can be conducted using mechanism-based inactivators and highlight studies with several classes of compounds including acetylenes, isothiocyanates, xanthates, aminobenzotriazoles, phencyclidine, and furanocoumarins. Labeled peptides isolated from the inactivated proteins have been analyzed by N-terminal amino acid sequencing in conjunction with mass spectrometry to determine the sites of covalent modification. Mechanistic studies aimed at identifying the basis for the inactivation following adduct formation are also presented.
Export Options
About this article
Cite this article as:
Kent M. Ute, Jushchhyshyn I. Monica and Hollenberg F. Paul, Mechanism-Based Inactivators as Probes of Cytochrome P450 Structure and Function, Current Drug Metabolism 2001; 2 (3) . https://dx.doi.org/10.2174/1389200013338478
DOI https://dx.doi.org/10.2174/1389200013338478 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Malignant Pleural Effusions: Review of Treatment and Our Experience
Reviews on Recent Clinical Trials Recent Developments in the Chemical Biology of Epothilones
Current Pharmaceutical Design Therapeutical Potential of CB<sub>2</sub> Receptors in Immune-Related Diseases
Current Molecular Pharmacology The Acute Phase Protein α1-Acid Glycoprotein: A Model for Altered Glycosylation During Diseases
Current Protein & Peptide Science Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells
Current Medicinal Chemistry Cyclooxygenase-2: Potential Role in Regulation of Drug Efflux and Multidrug Resistance Phenotype
Current Pharmaceutical Design Investigation of the Pharmacokinetics of the ABCG2 Transporter Inhibitor Ko134 in Mice by a Newly Developed and Validated HPLC Method
Current Pharmaceutical Analysis Intracellular Calcium, Endothelial Cells and Angiogenesis
Recent Patents on Anti-Cancer Drug Discovery Mitochondrial Superoxide Dismutase: A Promising Target for New Anticancer Therapies
Current Medicinal Chemistry Image-Guided Drug Delivery with Single-Photon Emission Computed Tomography: A Review of Literature
Current Drug Targets Apoptosis is a Critical Cellular Event in Cancer Chemoprevention and Chemotherapy by Selenium Compounds
Current Cancer Drug Targets Radionuclide Based Imaging of Prostate Cancer
Current Topics in Medicinal Chemistry Targeting Aurora Kinases in Cancer Treatment
Current Drug Targets Ligand-Protein Docking: Cancer Research at the Interface between Biology and Chemistry
Current Medicinal Chemistry Chrysin Induces Apoptosis in Peripheral Blood Lymphocytes Isolated from Human Chronic Lymphocytic Leukemia
Anti-Cancer Agents in Medicinal Chemistry siRNA Delivery by Stimuli-Sensitive Nanocarriers
Current Pharmaceutical Design Radiation Protection of the Child from Diagnostic Imaging
Current Pediatric Reviews Potential of DNMT and its Epigenetic Regulation for Lung Cancer Therapy
Current Genomics Oxidovanadium(IV) Complex Disrupts Mitochondrial Membrane Potential and Induces Apoptosis in Pancreatic Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry P53 Family: At the Crossroads in Cancer Therapy
Current Medicinal Chemistry